CLL: Venetoclax-Obinutuzumab Combo Effective Long Term

Patients with chronic lymphocytic leukemia (CLL) experience long-term progression-free survival benefits with 1 year of venetoclax plus obinutuzumab versus a chemotherapy-based regimen.

Related Keywords

Texas ,United States ,Houston ,Germany ,German ,Williamg Wierda ,Othman Al Sawaf ,Drug Administration ,Study Group ,University Of Texas Md Anderson Cancer Center ,Astrazeneca ,University Hospital Of Cologne Germany ,European Hematology Association ,European Hematology ,University Hospital ,Cancer Center ,Cumulative Illness Rating Scale ,Chronic Lymphocytic Leukemia ,Chemotherapy ,Biologic Therapy ,Thrombocytopenia ,Skin Cancer ,Alignant Skin Neoplasm ,Leukemia ,Lung Cancer ,Ung Carcinoma ,Ancer Lung ,Prostate Carcinoma ,Alignant Prostate Neoplasm ,Prostate Cancer ,Ancer Prostate ,Cancer ,Alignant Neoplasia ,Arcinoma ,Toxicology ,Tyrosine Kinase Inhibitor ,Rlotinib ,Efitinib ,Matinib ,U11248 ,Unitinib ,Non Hodgkins Lymphoma ,